Edgar Filing: ADMA BIOLOGICS, INC. - Form 4

ADMA BIOLO Form 4	OGICS, INC.								
February 16, 2	017								
FORM	4 UNITED	STATES		RITIES A			E COMMISSION		PPROVAL 3235-0287
Check this I if no longer subject to Section 16. Form 4 or Form 5 obligations may continu <i>See</i> Instruct 1(b).	STATEN Filed put te. Section 17(rsuant to S (a) of the F	CHAN ection (Public U	NGES IN SECUI 16(a) of th Jtility Hol	BENEF RITIES ne Securit Iding Con	ICIAL O' ies Excha	WNERSHIP OF nge Act of 1934, of 1935 or Sectio 940	Expires: Estimated burden hou response	urs per
(Print or Type Res	sponses)								
1. Name and Add Guiheen Lawr	ress of Reporting rence P.	Person <u>*</u>	Symbol	er Name an A BIOLO		Trading C. [ADM/	5. Relationship o Issuer A]	f Reporting Per	
(Last) (First) (Middle) C/O ADMA BIOLOGICS, INC., 465 STATE ROUTE 17			3. Date of Earliest Transaction (Month/Day/Year) 02/14/2017			Officer (give title Other (specify below) below)			
			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
RAMSEY, NJ	07446						Person	wore than one R	epotting
(City)	(State)	(Zip)	Tab	ole I - Non-J	Derivative	Securities A	Acquired, Disposed of	of, or Beneficia	lly Owned
	Transaction Date Ionth/Day/Year)	2A. Deeme Execution I any (Month/Da	Date, if	Code (Instr. 8)	4. Securiti onAcquired Disposed (Instr. 3, 4 Amount	(A) or of (D)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Reminder: Report	on a separate line	e for each cla	uss of sec	urities bene	ficially own		or indirectly.		
					Perso inform requir	ns who res nation cont ed to resp ys a curre	spond to the collect tained in this form ond unless the for ntly valid OMB co	are not m	SEC 1474 (9-02)

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: ADMA BIOLOGICS, INC. - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Y	ear) (Instr	. 8)	Acquired or Dispos (D) (Instr. 3, 4 and 5)	ed of				
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 5	02/14/2017	А		10,000		<u>(1)</u>	02/14/2027(2)	Common Stock	10,000

Reporting Owners

Reporting Owner Name / Address		Relationships						
r o	Director	10% Owner	Officer	Other				
Guiheen Lawrence P. C/O ADMA BIOLOGICS, INC. 465 STATE ROUTE 17 RAMSEY, NJ 07446	Х							
Signatures								
/s/ Lawrence	(12017)							

Guiheen	02/16/2017
<u>**</u> Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant.
- (2) The option terminates on the earlier of (i) February 14, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.